(Reuters) - The company, which focuses on developing products for neurology and psychiatry medical needs, said in an amended filing with the U.S. Securities and Exchange Commission that it plans to offer 6 million shares.
Read more at Reuters.com Bonds News
Read more at Reuters.com Bonds News
No comments:
Post a Comment